WithdrawnPHASE1, PHASE2NCT03304717

Reverse Transcriptase Inhibitors in Aicardi Goutières Syndrome

Studying Aicardi-Goutières syndrome

Last synced from ClinicalTrials.gov May 3, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Children's Hospital of Philadelphia
Principal Investigator: Adeline Vanderver, MD
Children's Hospital of Philadelphia
Intervention: Tenofovir (TDF) and Emtricitabine (FTC)(drug)
Eligibility: 2-18 years · All sexes
Timeline: 2025 – 2029

Collaborators

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · National Human Genome Research Institute (NHGRI) · Gilead Sciences · Emerson Resources · National Institutes of Health (NIH)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03304717 on ClinicalTrials.gov

← Back to all trials